The reason we ask questions directly to management is there is an underlying tone that is not open with this company. I highlighted that with Adam Logal during the conference call mentioning the repurchase of shares. That was a deflection from what was really going on… Yvonne tries to come across as being open at the investor relations department. As a former business owner, I can assure you what you get from investor relations is scripted to what has been publicly released only. Behind the scenes is a different world. We (our team of investors) are betting on some type of buyout. Elias is in his 70s, Frost is near 90. Those are the main characters. Both cut from the same mold…grow the business, then sell it. Very common practice.
What Yvonne tells about the current outstanding shares is only part of the story. In a buyout, many of those reserved shares would also have to be honored. So, being conservative 1,000,000,000 shares at this point would be the buyout amount. For example: a buyout at 7 dollars would represent a 7 billion dollar purchase. Modex has value potential we think. As many here have said, the lab has been a nemesis and OPKO has not reacted fast enough. There was a reason the former owner was happy to sell Bio for 1.5 billion. We can see clearly now. But what remains a mystery is why OPKO continues to fund it at a deficit in the hundreds of millions? On another note…
We will be traveling for a while until mid June to China. Until then, hopefully OPKO will have some good fortune during the interim.
AI
Market Data 
Markets 
